The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins, including tumor suppressors, and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and aggressive lymphomas. Oral selective inhibitor of nuclear export (SINE) compounds that block XPO1 function were recently identified and hold promise as a new therapeutic paradigm in many neoplasms. One of these compounds, KPT-330 (selinexor), has made progress in Phase I/II clinical trials, but systemic toxicities limit its administration to twice-per-week and requiring supportive care. We designed a new generation SINE compound, KPT-8602, with a similar mechanism of XPO1 inhibition and potency but considerably improved tolerability. Efficacy of KPT-8602 was evaluated in preclinical animal models of hematological malignancies, including CLL and AML. KPT-8602 shows similar in vitro potency compared with KPT-330 but lower central nervous system penetration, which resulted in enhanced tolerability, even when dosed daily, and improved survival in CLL and AML murine models compared with KPT-330. KPT-8602 is a promising compound for further development in hematological malignancies and other cancers in which upregulation of XPO1 is seen. The wider therapeutic window of KPT-8602 may also allow increased on-target efficacy leading to even more efficacious combinations with other targeted anticancer therapies.
INTRODUCTION
Nuclear-cytoplasmic transport of proteins is largely mediated by proteins of the karyopherin family of nuclear transport receptors. Exportin 1 (XPO1) is the best characterized exportin with 4200 cargos, including tumor-suppressor proteins (TSPs), such as p53, IκB and various RNAs. 1, 2 Proteins transported by XPO1 contain 10-15 residue nuclear export signals (NESs) that bind to a hydrophobic groove on XPO1. [3] [4] [5] [6] [7] Overexpression of XPO1 has been detected in many hematological 8 and solid tumors 9 and correlates with poor clinical outcomes. Increased levels of XPO1 in cancer cells promote egress of TSPs from the nucleus to the cytoplasm where they no longer regulate cell cycle, proliferation and apoptosis. Subcellular mislocalization of TSPs (for example, p53, BRCA1 and retinoblastoma) has been observed in cancer and has been linked to cancer progression and maintenance. 10 The importance of the XPO1-dependent nuclear export pathway is highlighted in a subset of adult acute myeloid leukemia (AML) patients with normal cytogenetics where mutations in the nucleophosmin (NPM1) gene (50-60% of cases) create a novel NES resulting in hyperactive XPO1-dependent export of NPM1.
11
NPM1's relocation to the nucleus (thereby restoring TSP function) represents a potential targeted therapy for this frequent subtype of AML. Additionally, XPO1 overexpression in AML correlates with poor clinical outcome. 12 In chronic lymphocytic leukemia (CLL), recurrent XPO1 mutations have also been described, 13 although the impact of these mutations remains uncertain.
Selective inhibitor of nuclear export (SINE) compounds, developed by Karyopharm Therapeutics Inc. (Newton, MA, USA), are orally bioavailable small molecules that covalently bind to Cys528 in the NES-binding groove of XPO1 and prevent NES/cargo binding and export. 14 Our previous published work showed that XPO1 is a therapeutic target for CLL 14 and AML 15, 16 and has facilitated the translation of a SINE compound named KPT-330 (selinexor) to a Phase I clinical trial in advanced hematological tumors (NCT01607892) and in multiple solid tumors (NCT01607905). Antitumor activity of selinexor has been observed in patients with diffuse large B-cell lymphoma (DLBCL), 17 CLL, 17 multiple myeloma 18 and AML. 19 To date 41000 patients have been treated with selinexor in Phase I/II clinical trials. Although constitutional symptoms (weight loss, fatigue, anorexia) were initially therapy limiting, selinexor tolerability has been improved with supportive care, consisting of appetite stimulants (megesterol plus olanzapine) and antinausea agents (odansetron). Hovewer, despite these improvements, the administration of selinexor is limited to twice per week at most. Therefore, continuous inhibition of XPO1 in cancer cells without unacceptable toxicity remains a challenge and new therapies are needed for the clinic.
In this report, we describe the structural, biochemical and in vivo characterization of a new generation SINE compound, KPT-8602, which shows similar target-binding properties as first-generation SINE compounds (KPT-185 and KPT-330) but reduced brain penetration and greater tolerability in preclinical animal models of hematological malignancies. The improved tolerability of KPT-8602 along with preserved target specificity suggest that it may have promising clinical efficacy in B-cell malignancies, AML and a variety of other cancers where upregulation of XPO1 is seen.
MATERIALS AND METHODS
Cloning, expression and protein purification Sc XPO1 (residues 1-1058 with residues 377-413 removed and Thr539 mutated to Cys) was cloned into the previously described pGEX-Tev vector. 20, 21 Residues 62-201 of Sc RanBP1 (Yrb1p) were also cloned into pGEX-TEV and full-length human Ran was cloned into the pET-15b vector. Further details are in Supplementary Materials.
Assembly of the XPO1-Ran-Yrb1 complex, crystallization and X-ray data collection KPT-8602-Sc XPO1-Ran-Yrb1 complex was crystallized in conditions similar to those used by Koyama and Matsuura 22 (17% PEG3350, 100 mM Bis-Tris (pH 6.6) and 200 mM ammonium nitrate). X-ray diffraction data was collected at Advanced Photon Source (APS)-Structural Biology Center (SBC) 19ID beamline. Further details are in Supplementary Materials.
In vitro inhibition assays
For inhibition assays, 2 μM purified XPO1 was incubated with the indicated inhibitor (0, 5, 10, 20 μM) and 10 μM RanGTP for 90 min at 4°C. The mixtures were then added to approximately 10 μg of immobilized NESs and rotated for 2 h at 4°C. Unbound proteins were washed extensively with buffer and remaining bound proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS/PAGE) and visualized by Coomassie Blue staining. For inhibition time-course experiments, incubation times of XPO1, RanGTP and inhibitors were varied, and the mixtures were rotated with immobilized GST-PKI NES for 1 h before extensive washing. Reversibility assays were performed as previously described. 21 Further details are in Supplementary Materials.
In vivo XPO1 degradation by SINE compound treatment
Human fibrosarcoma HT1080 cells were cultured and grown to 80% confluence. KPT-185, KPT-330 or KPT-8602 were added to final concentrations of 25-1000 nM, and cells were grown for another 18 h. Treated and control cells were collected by centrifugation and lysed on ice for 30 min in RIPA buffer. Further details are in Supplementary Materials.
Cell isolation and reagents
Human CLL and normal B cells were isolated and cultured as previously described. 14 Blood and frozen bone marrow aspirates from newly diagnosed untreated CLL and AML patients were obtained from the Ohio State University Leukemia Tissue Bank after getting informed consent approved by the cancer institution review board according to the Declaration of Helsinki. Further details are in Supplementary Materials.
Cell lysis and immunoblot
Cells were lysed in RIPA buffer. Nuclear extracts were prepared with NE-PER (Pierce, Waltham, MA, USA). Proteins were separated by SDS-PAGE, and the blots probed with commercially available antibodies and detected by addition of chemiluminescent substrate Pierce followed by quantification by Chemi-Doc system with the Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).
Assessment of cell death
Cell death was assessed using either Annexin-V/propidium iodide staining or MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay as previously described.
14 Further details are in Supplementary Materials.
Immunofluorescent staining
Approximately 200 000 cells were cytospinned to slide. Cells were then fixed, permeabilized, blocked and stained for confocal microscopy as previously described. 15 ) from MV4-11 transplanted NSG mice were intravenously injected into NSG mice via tail vein as previously described. 15 One week after tumor inoculation, mice were given vehicle control 5 × /week, KPT-8602 at 15 mg/kg 5 × /week (daily from Monday to Friday with a break Saturday-Sunday), KPT-8602 at 15 mg/kg 2 × /week, or KPT-330 at 20 mg/kg 2 × /week. Mice were monitored daily for clinical signs of leukemia, such as weight loss and hind-limb weakness/paralysis.
Statistics
All analyses were performed by the OSU Center for Biostatistics using previously described models.
14 For survival experiments, survival curve estimates were calculated using the Kaplan-Meier method, and differences in curves were assessed using the log-rank test. Spleen volume was compared between groups using analysis of variance, and mixed effects models were used to assess changes in %CD19+/CD5+ cells over time.
Where applicable, data were log-transformed to reduce skewness. P-values were adjusted for multiple comparisons using Holm's stepdown procedure or Dunnett's test, where appropriate. All analyses were performed using the SAS/STAT software, version 9.3 (SAS Institute, Inc., Cary, NC, USA).
RESULTS

KPT-8602 binds in the NES-binding groove of XPO1
The novel SINE, KPT-8602, forms a covalent bond with the same reactive cysteine that KPT-330 binds through a warhead with an activated Michael acceptor in the Cα that is similar to KPT-330's ( Figure 1a ). We have solved the 2.5 Å resolution X-ray structure of KPT-8602 bound to the Saccharomyces cerevisiae XPO1 ( KPT-8602 is oriented in the groove similar to other SINE compounds. 14, 23 The NES groove of XPO1 remains largely the same when bound to KPT-8602, KPT-185 or Leptomycin B (LMB; Cα rmsds of 0.2-0.3 Å).
14,21 KPT-185 is a first-generation SINE analog of KPT-330 that shares almost identical in vitro activities and the structure of its complex with XPO1 was previously reported. Although both KPT-185 and KPT-8602 contain a similar substitution (trifluoromethyl phenyl triazole) in the Cβ, the Michael acceptor of KPT-8602 is activated with a pyrimidyl group at the Cα. The trifluoromethyl phenyl core of KPT-185 and KPT-8602 interact with the XPO1 groove in a similar manner (Figure 1b and  Supplementary Table S2 
KPT-8602 inhibits XPO1-cargo interactions
We confirmed the ability of KPT-8602 to inhibit XPO1-NES interactions in a similar manner to other SINE compounds. We evaluated the ability of KPT-8602 to prevent pull-down of purified recombinant XPO1 with immobilized NESs. KPT-8602 successfully inhibited three different classical NESs/cargos ( PKI NES, MVM-NS2 NES and full-length Snurportin) efficiently (Figure 2a To confirm that the novel structure of KPT-8602 did not result in altered binding kinetics to XPO1, we assessed the reversibility of KPT-8602 conjugation to XPO1 as previously described. 21 Treatment with either dialysis or dithiothreitol to remove unconjugated/ deconjugated inhibitors was able to remove similar amounts of KPT-8602 and KPT-185 from XPO1 after 24 h, suggesting that KPT-8602 binds XPO1 in a slowly reversible manner similar to first-generation SINEs (Figure 2c) .
Finally, we examined inhibitor-induced degradation of XPO1 by KPT-8602. In addition to inhibition of NES-binding activity, proteasome-mediated degradation of XPO1 is another phenomenon that is consistently observed in KPT-treated cells. 8 The mechanism of this KPT-induced degradation of XPO1 is not understood. We also examined the effect of KPT-8602 treatment on proteasome-mediated degradation of XPO1. KPT-8602 induces XPO1 degradation in HT1080 cells in a dose-dependent manner similar to other SINE compounds, although higher concentrations of KPT-8602 are required to yield degradation responses similar to those with KPT-185 and KPT-330 (Figure 2d ). This phenomenon was also evaluated in human primary CLL cells. In contrast to HT1080 cell lines, KPT-8602 and KPT-330 decreased XPO1 total protein as early as 4 h posttreatment (Figure 2e ) with similar efficiency.
KPT-8602 induces apoptosis of primary CLL cells and significantly inhibits proliferation of diffuse large B-cell lymphoma cell lines The ability of KPT-8602 to induce cell death in primary CLL cells was evaluated. As shown in Figure 3a and Supplementary Figure S6 , treatment with KPT-8602 induced dose-dependent killing of primary CLL cells when compared with vehicle as measured by MTS analysis. We then tested the ability of selected concentrations of KPT-8602 to induce apoptosis of primary CLL cells in the presence of fetal bovine serum or human serum. As shown in Figure 3b , KPT-8602 was effective in inducing apoptosis of CLL cells in both fetal bovine serum and human serum.
We confirmed the effects of KPT-8602 on XPO1-dependent nuclear export by examining the cellular localization of IκB, a well-known cargo protein of XPO1, in human CLL cells after KPT-8602 treatment. Nuclear retention of IκB was observed within 8 h of treatment of KPT-330 and KPT-8602 (Supplementary Figure S2) . Next we assessed the ability of KPT-8602 to inhibit the proliferation of a panel of cell lines representative of DLBCL, both activated B-cell like (ABC-DLBCL) and germinal center subtypes (GC-DLBCL). As shown in Figure 3c , KPT-8602 inhibited proliferation in both ABC-DLBCL and GC-DLBCL cell lines (Figure 3d ).
KPT-8602 possesses reduced central nervous system penetration We assessed the capacity of KPT-8602 to cross the blood-brain barrier in three mammalian species (mouse, rat and monkey) compared with that of KPT-330 (selinexor), which is currently in clinical trials. As shown in Table 1 , KPT-8602 possesses a reduced central nervous system penetration in all species compared with KPT-330. Additionally, KPT-8602 does not accumulate in plasma after repetitive dosing (data not shown).
KPT-8602 prolongs survival in a mouse model of CLL The Eμ-TCL1 transgenic mouse develops a disease very similar to that observed in human CLL patients, and this model has been used extensively to evaluate experimental therapeutics in CLL. 25, 26 We and others have shown 27 that the B-cell malignancy occurring in the Eμ-TCL1 mice is amenable to adoptive cell transfer by engrafting splenic white blood cells from Eμ-TCL1 mice with active CLL-like leukemia (X10% CD45+CD5+CD19+ B cells in peripheral blood; white blood cell count 460) and palpable splenomegaly into the background strain WT C57BL/6 mice. This produces a homogeneous population with similar pathological findings to the Eμ-TCL1 transgenic mice and a more rapid disease acquisition (weeks instead of months), although time to disease and disease progression can be quite variable depending on the donor used for the engraftment.
We therefore employed the Eμ-TCL1-C57BL/6 transplant model described above to evaluate the potential of KPT-8602 to abrogate CLL progression in vivo. We hypothesized that increased reversibility combined with the lower brain penetration of KPT-8602 could reduce the development of constitutional symptoms (weight loss) and allow more frequent dosing, which would in turn impact its efficacy. C57BL/6 mice were engrafted with CD5+CD19+ splenocytes derived from a Eμ-TCL1 donor mouse with active disease. At the time of leukemia onset (defined as ⩾ 10% CD45+CD5+CD19+ cells), mice were randomized to receive KPT-8602, KPT-330 or vehicle control. Our group previously showed that KPT-330 dosed 3 × /week showed worse overall survival compared with KPT-330 dosed 2 × /week in this model. 26 We first compared KPT-8602 to KPT-330 by employing the clinically used schedule of administration via oral gavage 2 × /week as we previously described. 26, 28 As expected, mice treated with either compound showed similar overall survival, which was significantly improved over vehicle (P = 0.001 and 0.028, respectively) (Supplementary Figure S3) . KPT-8602 shows lower central nervous system penetration and mildly increased reversibility in XPO1-binding qualities that suggest an enhanced tolerability and wider therapeutic index compared with KPT-330. We therefore evaluated the therapeutic benefit of KPT-8602 dosed continuously vs 2 × /week in additional C57BL/6 mice engrafted with leukemic cells from a different Eμ-TCL1 donor. At leukemia onset, mice were randomized to receive vehicle or KPT-8602 daily or 2 × /week by oral gavage. Mice treated daily with KPT-8602 had significantly improved survival compared with those treated only 2 × /week (P = 0.001; Figure 4a ). Both daily and 2 × /week KPT-8602 provided significant survival benefit compared with vehicle treatment (Po0.001). Peripheral blood disease was evaluated weekly by CD45/CD5/CD19 (Figure 4b ). Spleen dimensions were taken when study removal criteria were met. Spleens derived from mice treated daily with KPT-8602 were significantly smaller compared with all the other groups (Po0.001, all comparisons) (Figure 4c ). Daily KPT-8602 treatment did not cause a significant change in body weight after 28 days of treatment (Supplementary Figure S4) . We have recently shown that the combination of KPT-330 and ibrutinib (bruton tyrosine kinase inhibitor) elicits a synergistic cytotoxic effect in primary CLL cells and increases overall survival compared with ibrutinib alone in a mouse model of CLL. 28 We therefore tested the effect of KPT-8602+ibrutinib in an additional cohort of C57BL/6 mice with engrafted leukemic cells from another Eμ-TCL1 donor. At leukemia onset, mice were randomized to receive vehicle, KPT-8602 (daily), ibrutinib (daily) or the combinations of KPT-330+ibrutinib or KPT-8602+ibrutinib. As shown in Figure 4d , the combination of KPT-8602+ibrutinib was able to further improve the survival induced by KPT-330+ibrutinib. Additionally, the percentage of leukemic cells in peripheral blood was similar for all groups at enrollment but was significantly lower in mice treated with the combination compared with mice treated with either agent alone or vehicle at week 2 (Po0.004, all comparisons; Figure 4e) . Similarly, at the last available flow cytometric analysis prior to killing owing to disease, peripheral blood disease was lower in mice treated with the combination compared with mice treated with ibrutinib alone or vehicle alone (Po0.001; Supplementary Figure S7 ). Spleens derived from mice treated daily with KPT-8602 or the combination were significantly smaller compared with vehicle or ibrutinib alone (Po0.001 for all comparisons; Figure 4f ).
KPT-8602 significantly inhibits proliferation and induces apoptosis of AML cell lines and primary AML blasts In order to assess the biological activity of KPT-8602 in AML, we treated a panel of AML cell lines (MV4-11, Kasumi-1, OCI/AML3) with KPT-8602 and KPT-330 and measured cell proliferation using MTS assays (Supplementary Figure S5) .
Treatment with KPT-8602 at the predetermined IC 50 values induced apoptosis in AML cell lines similar to KPT-330 when compared with DMSO-treated controls at 48 h (Figure 5a ). We then performed proliferation assays (WST-1) using primary AML samples (n = 3) using both KPT-8602 and KPT-330 and found comparable IC 50 for all patients, except one in which the IC 50 for KPT-8602 was higher (300 vs 100 nM) (Figure 5b ). The effect of KPT-8602 on the expression levels of two known XPO1 cargo proteins, p53 and NPM1, was assessed in AML cell lines after KPT-8602 treatment using confocal microscopy as described in the Materials and methods section. A significant accumulation of p53 and NPM1 in the nucleus of MV4-11 and OCI-AML3, respectively, were observed after treatment with KPT-8602 (Figure 5c More importantly, mice treated with KPT-8602 at 15 mg/kg but given 5 × /week showed strikingly better outcomes compared with KPT-8602 2 × /week (15 mg/kg, Po0.0001) and KPT-330 (20 mg/kg, 2 × /week, Po0.0001) (Figure 5d ). Peripheral blood was collected from mice in each treatment group at day 21 to assess the effect of KPT-8602 on circulating leukemia burden by measuring white blood cell count. Treatment with KPT-8602 (daily and 2 × /week) and KPT-330 significantly reduced white blood cell count in mice compared with those treated with vehicle (Figure 5e ).
DISCUSSION
LMB was the first clinically developed XPO1 inhibitor, 29 but suspected off-target effects on molecules such as cysteine proteases and lasting toxicity in the clinic led to abandonment of its clinical development. We now believe that the long-lasting toxicity of LMB is due to enhanced irreversibility of its conjugation to XPO1 as a result of XPO1-driven hydrolysis/modification of the drug. 21 Additionally, dose escalation studies of LMB and other synthetic nuclear export inhibitors in C57BL/6 mice suggest that low maximum tolerated dose of LMB limits its efficacy in vivo.
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Although SINE compounds also bind covalently to XPO1, they are considered slowly reversible inhibitors when compared with LMB. 21 The slowly reversible XPO1-SINE interaction is believed to contribute to the improved tolerance of SINEs over LMB as sufficient inhibitor release from XPO1 can allow essential nuclear export to resume in normal cells. This property has allowed rapid clinical development of selinexor. Despite notable clinical activity at a suboptimal dosing schedule for target inhibition based on the in vivo half-life of the compound, 17, 18 constitutional symptoms have been observed most likely owing to the ability of selinexor to cross the blood-brain barrier. Although these side effects have been mostly manageable with supportive care, they still represent a major limitation to administering SINE compounds at a frequency that provides sustained inhibition of XPO1 in cancer cells.
Our crystallographic and biochemical data show that KPT-8602 has a similar mechanism of XPO1 binding and inhibition as previous SINE compounds. We have also provided evidence that KPT-8602 inhibits XPO1 and induces similar nuclear retention of XPO1 targets similar to other SINE compounds, as expected. 14, 15 Additionally, KPT-8602 induces comparable levels of cytotoxicity as well as inhibition of cell proliferation compared with KPT-330 in primary CLL and AML tumors and a panel of cell lines representative of AML and both molecular subtypes of DLBCL. However, in contrast to KPT-330, KPT-8602 possesses reduced blood-brain barrier penetration in all analyzed species (mouse, rat and monkey), which likely contributes to improved tolerability.
KPT-8602 was tested in the Eu-TCL1-C57BL/6 transplant model of CLL. The resulting CLL-like leukemia is uniformly fatal to all recipients that successfully engraft; however, median survival for vehicle-treated mice in each experiment depends on donor characteristics, such as cell viability and leukemic burden. Additionally, oral gavage frequency may impact overall survival as demonstrated in median survival of vehicle-treated mice in Figures 4a and d where mice received daily and twice daily oral gavage, respectively. Although further studies remain to validate nuclear accumulation of cargo proteins such as p53 and NPM1 in vivo, our results using the MV4-11 xenograft mouse model complement recent elegant studies showing that KPT-8602 is superior to KPT-330 in its ability to eliminate leukemia-initiating cells in patient-derived xenograft models of AML. 31 Importantly, Etchin et al. 31 demonstrate that KPT-8602 spares normal CD34+ hematopoietic progenitor cells while modulating nucleocytoplasmic transport of XPO1 cargo proteins in leukemic cells in vivo.
Our data indicate that KPT-8602 allows a prolonged and frequent dosing schedule compared with KPT-330, leading to excellent therapeutic benefit and less toxicity in two murine models of hematological malignancies. These results are consistent with the lack of blood-brain barrier penetration; however, further studies are ) was measured at the time of killing for all mice meeting disease progression criteria. Black bars indicate averages of each cohort. Spleen volume in the KPT-8602 daily group was significantly lower compared with all other groups (Po0.001 for all comparisons). Analysis of variance was used to compare spleen volume (log-transformed) in KPT-8602 vs all other groups; P-values were adjusted using Dunnett's method. (d) Overall survival for C57BL/6 mice engrafted with Eμ-TCL1 leukemic splenocytes treated with ibrutinib 20 mg/kg daily (n = 5), ibrutinib plus KPT-8602 15 mg/kg daily (n = 6), ibrutinib plus KPT-330 15 mg/kg 2 × /week (n = 7), KPT-8602 15 mg/kg daily (n = 7) or vehicle control daily (n = 6). Median OS: 64 days (KPT-8602 plus ibrutinib), 43 days (KPT-330 plus ibrutinib), 26 (ibrutinib) and 20 days (vehicle). KPT-8602 plus ibrutinib increased survival compared with KPT-330 plus ibrutinib (P = 0.008). Survival comparisons were made with the log-rank test and adjusted for multiple comparisons. (e) CD45/CD5/CD19 flow cytometry of peripheral blood was used to assess leukemic burden weekly. Percentage of leukemic cell in peripheral blood was significantly lower in mice treated with KPT-8602 plus ibrutinib compared with vehicle, ibrutinib and KPT-8602 groups at 3 weeks after treatment initiation (Po0.004). A mixed effects model was used to assess changes in %CD19+/CD5+ cells over time. (f) Splenic volume (cm 3 ) was measured at the time of killing for all mice meeting disease progression criteria. Spleens in the combination group and KPT-8602 daily group were significantly smaller compared ibrutinib alone or vehicle (Po0.001 for all comparisons). required to elucidate the exact mechanism driving the increase in vivo tolerability of KPT-8602. Our data suggest that the wider therapeutic window of KPT-8602 may allow increased on-target efficacy leading to even more efficacious combinations with other targeted anticancer therapies 32 as exemplified by the combination of KPT-8602 with ibrutinib in a CLL mouse model.
In conclusion, we report here the preclinical therapeutic activity of the novel SINE compound, KPT-8602, an XPO1 antagonist, in CLL and AML murine models. Our results support further development of KPT-8602 as a novel therapeutic strategy for CLL and AML human patients.
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